HC Wainwright & Co. Reiterates Buy on Biora Therapeutics, Maintains $65 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Biora Therapeutics (NASDAQ:BIOR) and maintained a $65 price target.
August 15, 2023 | 10:47 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biora Therapeutics has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $65.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates a positive outlook for Biora Therapeutics. This could potentially lead to an increase in investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100